Zoetis Inc. $ZTS Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 77.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,728 shares of the company’s stock after selling 9,340 shares during the quarter. Fox Run Management L.L.C.’s holdings in Zoetis were worth $399,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Norges Bank acquired a new position in Zoetis in the second quarter valued at approximately $809,491,000. Diamond Hill Capital Management Inc. purchased a new position in shares of Zoetis during the 3rd quarter valued at approximately $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the period. Corient Private Wealth LLC boosted its holdings in Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after buying an additional 1,191,840 shares in the last quarter. Finally, Impax Asset Management Group plc boosted its holdings in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 1.0%

Shares of ZTS opened at $131.06 on Monday. The stock has a 50 day moving average price of $126.05 and a 200 day moving average price of $133.92. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The stock has a market capitalization of $55.32 billion, a price-to-earnings ratio of 21.77, a PEG ratio of 2.00 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the firm posted $1.40 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Barclays started coverage on shares of Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. The Goldman Sachs Group raised Zoetis to a “buy” rating in a report on Monday, December 15th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Bank of America boosted their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.